Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Treating inflammation using mesenchymal stem cells (MSCs) overexpressing P selectin glycoprotein ligand-1 (PSGL-1; CD162; SELPLG), Sialyl-LewisX (SLeX) and IL-10

MSCs overexpressing PSGL-1, SLeX and IL-10 could be used to treat inflammation. In mice with lipopolysaccharide (LPS)-induced ear inflammation, retro-orbitally injected MSCs transfected with Psgl-1 and SLeX-synthesizing a(1,3) fucosyltransferase (Fut7) mRNA had stronger interactions with the inflamed endothelium than unmodified MSCs. In the same model, systemically injected MSCs transfected with Psgl-1, Fut7 and Il-10 mRNA increased Il-10 levels in the ear and decreased inflammation by about 50% compared with injected MSCs transfected with Psgl-1 and Fut7 mRNA. Next steps include testing the MSCs in several preclinical animal models.
Wibi + Works LLC has Antimunocel, an anti-inflammatory, MSC-based product, in Phase I testing to treat rheumatoid arthritis (RA).

SciBX 6(39); doi:10.1038/scibx.2013.1114
Published online Oct. 10, 2013

Cell engineering approaches patented; available for licensing

Levy, O. et al. Blood; published online Aug. 26, 2013;
doi:10.1182/blood-2013-04-495119
Contact: Jeffrey M. Karp, Harvard Medical School, Boston, Mass.
e-mail:

jeffkarp.bwh@gmail.com